Guggenheim analyst Christopher Pasquale reiterated a Buy rating on Inspire Medical Systems Inc (NYSE: INSP) yesterday and set a price target of $60. The company’s shares closed yesterday at $45.54, close to its 52-week high of $50.00.
According to TipRanks.com, Pasquale is a 5-star analyst with an average return of 24.2% and a 76.6% success rate. Pasquale covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Edwards Lifesciences, and Abbott Labs.
Currently, the analyst consensus on Inspire Medical Systems Inc is a Moderate Buy with an average price target of $49.67, which is a 9.1% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $53 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $50.00 and a one-year low of $22.50. Currently, Inspire Medical Systems Inc has an average volume of 217.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inspire Medical Systems, Inc. engages in the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control, and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead.
